Table 1:
These are the descriptive characteristics of patients who received RFA in the MarketScan database compared to those who did not.
| RFA Cohort n (%) | Non-RFA Cohort n (%) | RFA Rate per 100,000 Enrollees | |
|---|---|---|---|
| Overall | 165,734 (100.0) | 149,665,356 (100.0) | 111 |
| Age (Years) | |||
| < 35 | 15,177 (9.2) | 83,983,167 (56.1) | 18 |
| 35 – 44 | 31,386 (18.9) | 23,927,326 (16.0) | 131 |
| 45 – 54 | 55,773 (33.7) | 23,819,717 (15.9) | 234 |
| 55 – 64 | 63,342 (38.2) | 17,919,831 (12.0) | 352 |
| 65 – 74 | 56 (0.0) | 15,315 (0.0) | 364 |
| Sex | |||
| Female | 99,418 (60.0) | 76,326,706 (51.0) | 130 |
| Male | 66,316 (40.0) | 73,338,650 (49.0) | 90 |
| Employment Status | |||
| Full Time | 62,727 (37.8) | 52,414,298 (35.0) | 120 |
| Part Time | 1,133 (0.7) | 1,246,824 (0.8) | 91 |
| Retired | 14,797 (8.9) | 2,908,233 (1.9) | 506 |
| Long Term Disability | 1,365 (0.8) | 89,516 (0.1) | 1,502 |
| Other/Unknown | 85,712 (51.7) | 93,006,485 (62.1) | 92 |
| Health Insurance Plan | |||
| Comprehensive | 5,379 (3.2) | 1,662,695 (1.1) | 322 |
| Exclusive/PPO | 106,546 (64.3) | 69,071,402 (46.2) | 154 |
| HMO | 19,397 (11.7) | 13,381,730 (8.9) | 145 |
| POS | 13,879 (8.4) | 7,056,669 (4.7) | 196 |
| CDHD | 11,950 (7.2) | 7,689,095 (5.1) | 155 |
| Unknown | 8,583 (5.2) | 50,803,765 (33.9) | 17 |
| Geographic Region | |||
| Northeast | 20,962 (12.6) | 25,018,521 (16.7) | 84 |
| North Central | 36,845 (22.2) | 33,137,110 (22.1) | 111 |
| South | 77,709 (46.9) | 59,218,155 (39.6) | 131 |
| West | 26,902 (16.2) | 27,890,777 (18.6) | 96 |
| Missing | 3,316 (2.0) | 4,400,793 (2.9) | 75 |
| Charlson Comorbidity Score* | |||
| 0 | 63,434 (57.9) | 127,371 (84.9) | 76 |
| 1 – 2 | 35,718 (32.6) | 19,399 (12.9) | 280 |
| 3 – 4 | 7,473 (6.8) | 2,251 (1.5) | 502 |
| 5+ | 2,899 (2.6) | 979 (0.7) | 411 |
Abbreviations: RFA - radiofrequency ablation; PPO - exclusive/ preferred provider organization; HMO - health maintenance organization; POS - point of service; CDHD - consumer-directed/high-deductible.
*
In the RFA cohort, Charlson Comorbidity Scores, for all patients with at least one year of enrollment prior to RFA, were calculated to determine the distribution. One year of enrollment was required to allow for adequate time for comorbidities to be recorded. In the non-RFA cohort, a random sample of 150,000 patients with one year of enrollment (~0.1%) was used to estimate the distribution.